175.90
前日終値:
$176.57
開ける:
$176.3
24時間の取引高:
1.50M
Relative Volume:
1.19
時価総額:
$19.80B
収益:
$9.54B
当期純損益:
$841.00M
株価収益率:
23.64
EPS:
7.44
ネットキャッシュフロー:
$1.02B
1週間 パフォーマンス:
-0.80%
1か月 パフォーマンス:
+10.08%
6か月 パフォーマンス:
+10.37%
1年 パフォーマンス:
+29.21%
Quest Diagnostics Inc Stock (DGX) Company Profile
DGX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
DGX
Quest Diagnostics Inc
|
175.90 | 19.80B | 9.54B | 841.00M | 1.02B | 7.44 |
![]()
TMO
Thermo Fisher Scientific Inc
|
410.78 | 158.51B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
194.82 | 140.78B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
489.98 | 37.91B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
108.70 | 31.23B | 6.53B | 1.26B | 1.31B | 4.35 |
![]()
IQV
Iqvia Holdings Inc
|
153.29 | 26.31B | 15.41B | 1.37B | 2.11B | 7.50 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-02 | 開始されました | Redburn Atlantic | Buy |
2025-03-04 | ダウングレード | Citigroup | Buy → Neutral |
2025-01-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
2024-12-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2024-12-10 | 再開されました | Jefferies | Buy |
2024-10-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
2024-08-28 | 再開されました | Evercore ISI | In-line |
2024-07-10 | アップグレード | Citigroup | Neutral → Buy |
2024-02-26 | 開始されました | Leerink Partners | Market Perform |
2024-02-07 | アップグレード | Jefferies | Hold → Buy |
2024-01-03 | 開始されました | Barclays | Equal Weight |
2023-12-12 | アップグレード | BofA Securities | Neutral → Buy |
2023-06-29 | 開始されました | Piper Sandler | Neutral |
2023-05-02 | ダウングレード | BofA Securities | Buy → Neutral |
2023-04-03 | アップグレード | Citigroup | Sell → Neutral |
2023-01-23 | 開始されました | Evercore ISI | In-line |
2022-11-17 | ダウングレード | Citigroup | Neutral → Sell |
2022-08-22 | 再開されました | Morgan Stanley | Equal-Weight |
2022-04-04 | ダウングレード | Citigroup | Buy → Neutral |
2022-02-23 | ダウングレード | UBS | Buy → Neutral |
2022-02-02 | ダウングレード | Jefferies | Buy → Hold |
2022-01-28 | ダウングレード | Deutsche Bank | Buy → Hold |
2021-05-04 | アップグレード | UBS | Neutral → Buy |
2021-03-12 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2020-10-21 | アップグレード | Argus | Hold → Buy |
2020-07-29 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
2020-07-14 | アップグレード | BofA Securities | Neutral → Buy |
2020-06-09 | アップグレード | Wells Fargo | Underweight → Equal Weight |
2020-06-02 | アップグレード | Deutsche Bank | Hold → Buy |
2020-04-28 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-04-27 | アップグレード | Citigroup | Neutral → Buy |
2020-04-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
2020-03-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-01-08 | 開始されました | Wells Fargo | Underweight |
2020-01-07 | ダウングレード | Barclays | Overweight → Equal Weight |
2019-12-19 | アップグレード | BofA/Merrill | Underperform → Neutral |
2019-07-15 | ダウングレード | Goldman | Neutral → Sell |
2019-04-02 | アップグレード | Jefferies | Hold → Buy |
2019-03-18 | 再開されました | Credit Suisse | Neutral |
2019-01-31 | ダウングレード | Argus | Buy → Hold |
2019-01-17 | 開始されました | UBS | Neutral |
2019-01-03 | ダウングレード | BofA/Merrill | Neutral → Underperform |
2018-12-03 | ダウングレード | BofA/Merrill | Buy → Neutral |
2018-11-30 | ダウングレード | Goldman | Buy → Neutral |
すべてを表示
Quest Diagnostics Inc (DGX) 最新ニュース
Global Immunodiagnostics Market to Cross the USD 32 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Quest Diagnostics (DGX) Sees Raised Target Price by JP Morgan | - GuruFocus
Quest Diagnostics (DGX) Receives Price Target Increase from JPMo - GuruFocus
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus - MSN
Quest Diagnostics Stock: A Leader But Waiting For Better Price (NYSE:DGX) - Seeking Alpha
Quest Settles Fired Black Phlebotomist's Retaliation Suit - Law360
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook By Investing.com - Investing.com Canada
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook - Investing.com
Piper Sandler Adjusts Price Target on Quest Diagnostics to $200 From $180, Maintains Neutral Rating - marketscreener.com
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Benzinga
Truist Financial Keeps Their Hold Rating on Quest Diagnostics (DGX) - The Globe and Mail
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings - Benzinga
Morgan Stanley Adjusts Quest Diagnostics Price Target to $182 From $172, Maintains Overweight Rating - marketscreener.com
Baird Adjusts Quest Diagnostics Price Target to $194 From $191, Maintains Outperform Rating - marketscreener.com
Jefferies Adjusts Quest Diagnostics Price Target to $195 From $190, Maintains Buy Rating - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Increase Following Str - GuruFocus
Mizuho Securities Adjusts Quest Diagnostics Price Target to $190 From $189 - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Increase Following Strong Q1 Results | DGX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Quest Diagnostics Through 12 Analysts - Benzinga
Quest Diagnostics Incorporated (NYSE:DGX) Q1 2025 Earnings Call Transcript - Insider Monkey
Truist Raises Price Target on Quest Diagnostics to $190 From $182, Keeps Hold Rating - marketscreener.com
Quest Diagnostics (DGX) Sees Price Target Boost from Barclays | - GuruFocus
Quest Diagnostics (DGX) Sees Price Target Boost from Barclays | DGX Stock News - GuruFocus
Quest Diagnostics (DGX) Stock Analysis: Unpacking the 5.32% Potential Upside for Investors - DirectorsTalk Interviews
Quest Diagnostics Inc (DGX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Quest Diagnostics Inc (DGX) Q1 2025 Earnings Call Highlights: St - GuruFocus
Quest Diagnostics Inc (DGX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations - GuruFocus
Quest Diagnostics: Q1 Earnings Snapshot - CTPost
Quest Diagnostics earnings bolstered by March rebound, sending stock up 3% - MSN
Barclays Raises Quest Diagnostics' Price Target to $185 From $175 - marketscreener.com
Evercore ISI Adjusts Quest Diagnostics Price Target to $180 From $175 - marketscreener.com
Quest Diagnostics Inc (DGX) Trading 6.97% Higher on Apr 22 - GuruFocus
Quest Diagnostics (DGX) Reports Strong Q1 2025 Revenue Growth - GuruFocus
Leerink Adjusts Price Target on Quest Diagnostics to $189 From $184 - marketscreener.com
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook ConfidenceQuest Diagnostics (NYSE:DGX) - Benzinga
Quest Diagnostics (DGX) Increases EPS Outlook After Strong Q1 Performance - GuruFocus
Quest Diagnostics Q1 Earnings & Revenues Top Estimates, Stock Up - Nasdaq
Quest Diagnostics up 8% following earnings beats, EPS guidance raise - Seeking Alpha
Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On TuesdayAkso Health (NASDAQ:AHG), Bitdeer Technologies (NASDAQ:BTDR) - Benzinga
Quest Diagnostics Shines With Strong Profits And Revenue Growth - Finimize
Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025 - The Malaysian Reserve
Quest Diagnostics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Quest Diagnostics’ Q1 Earnings Align With Wall Street Estimates: Retail’s In Wait-And-Watch Mode - MSN
Quest Diagnostics (DGX) Q1 Earnings and Revenues Beat Estimates - Yahoo
Quest beats quarterly profit estimates on strong demand for diagnostic tests - marketscreener.com
Strong Q1 Revenue Performance by Quest Diagnostics (DGX) Exceeds Projections | DGX Stock News - GuruFocus
Quest Diagnostics Inc (DGX) Q1 2025 Earnings: EPS of $1.94 Beats Estimate, Revenue Hits $2.65 Billion - GuruFocus
Quest Diagnostics Q1 Adjusted Earnings, Revenue Increase; 2025 Adjusted Earnings Outlook Affirmed - marketscreener.com
Quest Diagnostics (DGX) Beats Q1 Estimates, Adjusts FY25 Guidance - GuruFocus
Quest Diagnostics Inc (DGX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):